Biomerica, Inc. (BMRA)

From the record

Biomerica, Inc.'s filings since 2017 show 4 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2024-11-06); a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-09-30); an auditor change (8-K item 4.01, the latest 2022-04-19) (its current reports).

From the record

Biomerica, Inc.'s 10 filed years say what it did: revenue went from $6 million in fiscal 2017 to $4 million in fiscal 2026, down 2.9% a year; it rose in 4 of 9 years; the deepest fall was 76% from fiscal 2022 to fiscal 2026; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2026-05-31, Biomerica, Inc. lost about 144 cents for every dollar of shareholders' money, and gross profitability: its products earned about 5 cents per dollar of everything the company owns. Leverage: it owed about 61 cents per dollar of assets, and net share issuance: its share count grew 26.9% over the year (the filed statements).

From the record

Biomerica, Inc.'s standing among 17 graded names in its industry family: revenue of $4 million in fiscal 2026 ranks in the bottom 38% by size; a net margin of -84.8% ranks in the bottom 44%; revenue growth of -5.9% a year over the last 3 filed years ranks in the bottom 28% (its annual reports).

From the record

Biomerica, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Irani, Zackary S. (Chief Executive Officer, as filed), filing under that title since 2016-09-09, 10.2 years (top 21% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 3.2 years (bottom 25%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (bottom 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Biomerica, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $1 million against no long-term debt tagged leaves 19.4% of its assets as net cash, top 31% of its family; cash from operations less capital spending is -76.8% of revenue (bottom 47%); a gross margin of 8.1% (bottom 13%); research spending of 17.7% of revenue (top 41%) (its annual report).

From the record

Biomerica, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew -5.9% a year over the last three filed years against -2.9% over all 10, slowing (bottom 43% of its family); the newest year grew -16.2% (bottom 21%); research spending grew -20.8% a year (bottom 15%); capital spending grew -27.9% a year (top 50%) (its annual reports). Biomerica, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Biomerica, Inc.'s newest year against its own record: revenue of $4 million in fiscal 2026 came in 15.9% below the $5 million its prior three years' pace pointed to (bottom 30% of its family); net income of $4 million against a prior three-year average of $6 million (top 22%); a net margin of -84.8% against losses larger than its revenue before (top 47%) (its annual reports).